438 Studies Now Enrolling
An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (Vdomain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects with Advanced Cancer
A study for patients with advanced cancers using study drug JNJ-61610588
| Sponsor: | Johnson & Johnson |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ6109 |
| Contact: | Catherine Shu: 212-305-3997 / cas2145@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to see if JNJ-61610588 is safe and useful for treating patients with cancer. Another purpose is to find out how long JNJ-61610588 stays in and acts on your body and how your body responds to it. The first part will find the dose of JNJ-61610588 that would be best to give to cancer patients. (A dose is measured amount of drug taken at one time.) The safety and side effects of different doses of JNJ-61610588 will be explored. The second part will look at how cancer responds to safe dose of JNJ-61610588. Only patients with non-small cell lung cancer can participate in this part of the study.
This study is closed
